Investors are suing Unicycive Therapeutics, a biopharmaceutical company, alleging that the company made false or misleading statements about its business, operations, and prospects in violation of federal securities laws. The plaintiffs claim that the company's public disclosures painted an overly optimistic picture, which artificially inflated the stock price. When the true state of affairs allegedly became known to the market, investors suffered significant financial losses as the stock price declined. The proposed class consists of people who purchased or acquired Unicycive Therapeutics securities during a specific time period and lost money as a result of the alleged misconduct. The lawsuit seeks to recover those losses on behalf of affected shareholders.
The case is in its earliest stage. The defendant has not yet responded. Class certification — the court's decision on whether the case can proceed as a class action — typically takes 12 to 24 months after filing.
Source: CourtListener docket entry. This summary was generated automatically and may not reflect subsequent filings.
A participating attorney may be able to evaluate your claim at no cost to you.